Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PIb/II, Open-label, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of I.V. Olvi-Vec Combined With Platinum Plus Etoposide in Patients With Advanced SCLC Who Are Platinum-recurrent or Platinum-refractory

NCT07136285 is registered in ClinicalTrials.gov with Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd. as lead sponsor.

NCT NCT07136285
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07136285 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PIb/II, Open-label, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of I.V. Olvi-Vec Combined With Platinum Plus Etoposide in Patients With Advanced SCLC Who Are Platinum-recurrent or Platinum-refractory
Lead sponsor
Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 24, 2023
Completion date
December 31, 2026
Enrollment
27 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

sclc, extensive stage